Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 509 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia / Schizoaffective Disorder Clear all
Completed Phase 4 Interventional Results available

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

NCT00690235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions
Pramlintide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Not applicable Interventional

Financial Incentives to Improve Medication Adherence

NCT04191876
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depression
Interventions
Wellth - Financial Incentives
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Phase 3 Interventional

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

NCT05658510
View directory record Official record
Conditions
Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
BXCL501, Matching Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Bellflower, California • Cerritos, California • Culver City, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 15, 2026, 10:35 AM EDT
Recruiting Phase 2 Interventional

Synbiotic Compound to Reduce Symptoms of Schizophrenia

NCT04226898
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Synbiotic Supplement, Inert Compound
Biological
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Batlimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 15, 2026, 10:35 AM EDT
Active, not recruiting Not applicable Interventional

EPI-MINN: Targeting Cognition and Motivation - National

NCT05877716
View directory record Official record
Conditions
Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions
Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care
Device · Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
15 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 10:35 AM EDT
Not listed Phase 4 Interventional

Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia

NCT00469664
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Cognitive Impairment
Interventions
Guanfacine/Tenex
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
3
States / cities
New York, New York • The Bronx, New York • W. Brentwood, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2008 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

NCT00176423
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
galantamine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Phase 3 Interventional

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

NCT00095524
View directory record Official record
Conditions
Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
23
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 15, 2026, 10:35 AM EDT
Terminated Phase 2 Interventional Results available

Telmisartan Pilot Study on Treatment Resistant Schizophrenia

NCT03868839
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
Interventions
Telmisartan Pill
Drug
Lead sponsor
Xiaoduo Fan
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Phase 3 Interventional Results available

D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia

NCT00237809
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
D-serine, Cognitive Retraining (CRT), Placebo, Cognitive Retraining Placebo
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Not applicable Interventional

Evaluation of mHealth for Serious Mental Illness

NCT04068467
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depressive Disorder, Bipolar Disorder
Interventions
Smartphone App, Waitlist Control
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Not applicable Interventional Results available

Motivation Skills Training for Schizophrenia

NCT05746455
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Motivation Skills Training (MST)
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Not applicable Interventional

Cognitive Remediation and Social Skills Training in Schizophrenia

NCT00223535
View directory record Official record
Conditions
Schizophrenia, Schizoaffective
Interventions
Cognitive Remediation, Social Skills Training
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2005 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Phase 4 Interventional

Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder

NCT00501618
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Fazaclo
Drug
Lead sponsor
Manhattan Psychiatric Center
Other
Eligibility
18 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Not applicable Interventional Results available

Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders

NCT01487668
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder, Cardiovascular Disease Risk
Interventions
Life Goals Collaborative Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Not applicable Interventional

Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)

NCT03183609
View directory record Official record
Conditions
Schizophrenia, Gluten Sensitivity, Schizo Affective Disorder
Interventions
Gluten Flour in Protein Shake, Rice Flour in Protein Shake
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clozapine CHAMPION-ECHO Educational Study to Improve Clozapine Use.

NCT04325386
View directory record Official record
Conditions
Schizophrenia Schizoaffective
Interventions
ECHO Intervention, eTAU
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
22 Years to 85 Years
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 15, 2026, 10:35 AM EDT
Completed No phase listed Observational

Effects of Antipsychotic Medications on Energy Intake and Expenditure

NCT00836251
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Weight Gain
Interventions
H218O and 2H2O, administered as a mixed cocktail
Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Phase 2 Interventional Results available

Biomarkers in Schizophrenia

NCT00817336
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
D Serine, Placebo
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Not applicable Interventional

Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

NCT02566057
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders, Bipolar Disorder
Interventions
PGx testing guided treatment (PGT)
Biological
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Not applicable Interventional Results available

Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial

NCT04173572
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorders, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions
PACE-Life, Exercise Intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Phase 2Phase 3 Interventional

Adjunctive Treatment for Decreasing Symptoms of Schizophrenia

NCT00222235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
d-cycloserine, glycine, placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 54 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Glen Oaks, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

NCT02411526
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 15, 2026, 10:35 AM EDT
Completed Not applicable Interventional Results available

Lifestyle Intervention for Young Adults With Serious Mental Illness

NCT02815813
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Overweight, Obesity
Interventions
PeerFIT, BEAT
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
New Britain, Connecticut • Nashua, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 15, 2026, 10:35 AM EDT